Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review

Table 5 Summary of efficacy outcomes from newly included studies

Ref.	Time point	EASI 75 (%)	IGA 0/1 (%)	Itch NRS ≥ 4-point (%)	Key findings
Warren et al[2], 2025 (ADvantage)	Week 16	52.1 vs 22.0 (placebo)a	32.5 vs 11.4 (placebo)a	Not reported	Efficacy in ciclosporin-inadequate population
Guttman-Yassky et al[1], 2025 (ADjoin)	Week 104	Maintained in 84.3% (Q2W) and 82.9% (Q4W)	Maintained in 76.5% (Q2W) and 74.8% (Q4W)	Not reported	Durable long-term response
Tanaka et al[3], 2024	Week 52	Not reported	Not reported	Significant improvement	Improved quality of life and PROs
Avallone et al[4], 2025 (Italy RWE)	Week 16	65.2	58.4	72.3	Real-world effectiveness confirmed
Avallone et al[4], 2025 (Italy RWE)	Week 24	71.6	64.1	78.5	Continued improvement over time
Abraheem et al[5], 2025 (United Kingdom RWE)	Week 16	72.7	66.4	Median -5 points	Effective in biologic-experienced patients
Hagino et al[6], 2025 (Japan RWE)	Week 24 (bio-naive)	78.3	Not reported	Not reported	Highest response in treatment-naive
Hagino et al[6], 2025 (Japan RWE)	Week 24 (prior JAKi)	69.8	Not reported	Not reported	Maintained efficacy after JAKi
Hagino et al[6], 2025 (Japan RWE)	Week 24 (prior biologic)	66.2	Not reported	Not reported	Maintained efficacy after biologic

^aP < 0.001 for lebrikizumab vs placebo.

EASI: Eczema Area and Severity Index; IGA: Investigator global assessment; JAKi: Janus kinase inhibitor; NRS: Numeric rating scale; PROs: Patient-reported outcomes; Q2W: Every 2 weeks; Q4W: Every 4 weeks; RWE: Real-world evidence.